-
ALSO READ
AstraZeneca Pharma India terminates distribution services agreement with Sun Pharma
Sun Pharma gains after licensing agreement with Ferring Pharma for Caritec in India
Sun Pharma Q4 PAT jumps 124% to Rs 894 cr
Board of Sun Pharma Advanced Research Company to consider fund raising options
Indices trim losses; pharma shares advance
-
Sun Pharmaceutical Industries rose 1.54% to Rs 824.25 after the company's consolidated net profit rose 12.92% to Rs 2047.01 crore on 12.54% increase in net sales to Rs 9625.93 crore in Q2 September 2021 over Q2 September 2020.
On a consolidated basis, profit before tax (PBT) rose 19.26% to Rs 2,286.51 crore in Q2 September 2021 over Q2 September 2020.The company's total expenses in the quarter rose 9.7% year-on-year to Rs 7,562.31 crore.
Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU